Flex Pharma, Inc. (NASDAQ:FLKS) Files An 8-K Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure.
On November 15, 2016, Flex Pharma, Inc. will present a poster
entitled “Chemical Neuro Stimulation of TRPV1 and TRPA1 Sensory
Neurons Decreases Muscle Cramps in Humans” at the Society for
Neuroscience Conference. The poster is furnished herewith as
Exhibit 99.1.
entitled “Chemical Neuro Stimulation of TRPV1 and TRPA1 Sensory
Neurons Decreases Muscle Cramps in Humans” at the Society for
Neuroscience Conference. The poster is furnished herewith as
Exhibit 99.1.
The information contained in this Item 7.01 and Exhibit 99.1
attached hereto shall not be deemed “filed” for purposes of
Section 18 of the Securities and Exchange Act of 1934, as
amended, or otherwise subject to the liabilities of that section,
nor shall it be deemed incorporated by reference in any filing
under the Securities Act of 1933, as amended, except as expressly
set forth by specific reference in such filing.
attached hereto shall not be deemed “filed” for purposes of
Section 18 of the Securities and Exchange Act of 1934, as
amended, or otherwise subject to the liabilities of that section,
nor shall it be deemed incorporated by reference in any filing
under the Securities Act of 1933, as amended, except as expressly
set forth by specific reference in such filing.
Item 9.01. >>Financial Statements and Exhibits.
(d) >Exhibits
The following exhibit relating to Item 7.01 shall be deemed to be
furnished and not filed:
furnished and not filed:
|
Exhibit No.
|
Description
|
||
|
99.1
|
Flex Pharma, Inc. Poster
|
||
About Flex Pharma, Inc. (NASDAQ:FLKS)
